Drugs / TQG203
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04768699 | Dec 2020 → Dec 2021 | hemophilia A, hemophilia B | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQG203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04768699 ↗ |
| Known as | FⅦa | “Aim of this trial is to assess the pharmacokinetics and pharmacodynamics (PK/PD) of recombinant human coagulation factor VIIa for injection (FⅦa) in patients with hemophilia.” NCT04768699 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human coagulation factor VIIa for injection” NCT04768699 ↗ |
| Route | Intravenous | “administered as intravenous (i.v.) administration” NCT04768699 ↗ |